Yong Li

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

Xiaotian Zhang, Liang Han, Ziyu Li et al. · The Lancet Oncology · 2021 · 414 citations

D2 Gastrectomy, Surgical Oncology, Esophageal Cancer +10

Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study

Ping’an Ding, Honghai Guo, Chenyu Sun et al. · BMC Gastroenterology · 2022 · 152 citations · Full text

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial

Honghai Guo, Ping’an Ding, Chenyu Sun et al. · Frontiers in Oncology · 2022 · 45 citations · Full text

Highly Expressed Granulocyte Colony-Stimulating Factor (G-CSF) and Granulocyte Colony-Stimulating Factor Receptor (G-CSFR) in Human Gastric Cancer Leads to Poor Survival

Zhisong Fan, Yong Li, Qun Zhao et al. · Medical Science Monitor · 2018 · 38 citations · Full text

Immunology, Gastroenterology, Pathology +17

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial

Xiaotian Zhang, Liang Han, Ziyu Li et al. · The Lancet Oncology · 2025 · 32 citations

D2 Gastrectomy, Surgical Oncology, Esophageal Cancer +10